Morphoconstitutional analysis of urinary calculi, i.e. morphologic examination combined with Fourier transform infrared spectroscopy (FTIR), is of decisive interest for the diagnosis of rare but severe inherited or acquired stone diseases such as cystine, 2,8-dihydroxyadenine, xanthine, struvite, ammonium urate or drug-containing calculi as well as primary hyperoxalurias. In the absence of early diagnosis and proper management, these diseases may lead to progressive loss of renal function. Among common forms of calcium oxalate (CaOx) stones, predominant CaOx monohydrate (whewellite) is mainly associated with hyperoxaluric conditions whereas predominant CaOx dihydrate (weddellite) is mainly associated with hypercalciuria, and this distinction is of interest to orient metabolic evaluation and preventive measures. Crystalluria examination, also based on morphology and FTIR, is a valuable diagnostic method when no stone is available for analysis. Presence of specific crystals (cystine, 2,8-dihydroxyadenine, struvite, ammonium urate) is diagnostic by itself. In all types of nephrolithiasis, serial crystalluria determination appears as a simple, cheap and reliable method to evaluate the risk of stone formation and assess the effectiveness of preventive measures. Determination of urinary crystal volume was in our experience a useful tool in the management of patients with cystinuria or primary hyperoxaluria in the post-transplantation period. In conclusion, both accurate morphologic and FTIR analysis of stones and serial crystalluria determination should be more largely used, in view of their value in the diagnosis and management of renal stone formers.

Keywords:
Crystalluria, Crystal volume, Infrared spectroscopy, Morphology, Stone analysis
1.
Azoury R, Garside J, Robertson WG: Calcium oxalate precipitation in a flow system: An attempt to simulate the early stages of stone formation in renal tubules. J Urol 1986;136:150–153.
2.
Hess B, Meinhardt U, Zipperle L, Giovanoli R, Jaeger P: Simultaneous measurements of calcium oxalate crystal nucleation and aggregation: Impact of various modifiers. Urol Res 1995;23:231–238.
3.
Kavanagh JP, Jones L, Rao PN: Calcium oxalate crystallization kinetics at different concentrations of human and artificial urine, with a constant calcium to oxalate ratio. Urol Res 1999;27:231–237.
4.
Tiselius HG, Hallin A, Lindbäck B: Crystallisation properties in stone forming and normal subjects’ urine diluted using a standardised procedure to match the composition of urine in the distal part of the distal tubule and the middle part of the collecting duct. Urol Res 2001;29:75–82.
5.
Winkens RA, Wielders JP, Degenaar CP, van Hoof JP: Calcium oxalate crystalluria, a curiosity or a diagnostical aid? J Clin Chem Clin Biochem 1988;26:653–654.
6.
Robert M, Boularan AM, Delbos O, Guiter J, Descomps B: Study of calcium oxalate crystalluria on renal and vesical urines in stone formers and normal subjects. Urol Int 1998;60:41–46.
7.
Pak CYC, Poindexter JR, Adams-Huet B, Pearle M: Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med 2003;115:26–32.
8.
Robertson WG, Peacock M, Nordin BE: Calcium crystalluria in recurrent renal-stone formers. Lancet 1969;2:21–24.
9.
Hallson PC, Rose GA: Crystalluria in normal subjects and in stone formers with and without thiazide and cellulose phosphate treatment. Br J Urol 1976;48:515–524.
10.
Hallson PC, Rose GA: A new urinary test for stone ‘activity’. Br J Urol 1978;50:442–448.
11.
Werness PG, Bergert JH, Smith LH: Crystalluria. J Crystal Growth 1981;53:166–181.
12.
Robertson WG, Peacock M, Marshall RW, Marshall DH, Nordin BE: Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. New Engl J Med 1976;294:249–252.
13.
Ahlstrand C, Tiselius HG, Larsson L: Studies on crystalluria in calcium oxalate stone formers. Urol Res 1984;12:103–106.
14.
Bader CA, Chevalier A, Hennequin C, Jungers P, Daudon M: Methodological aspects of spontaneous crystalluria studies in calcium stone formers. Scanning Microsc 1994;8:215–231.
15.
Jouvet P, Priqueler L, Gagnadoux MF, Jan D, Beringer A, Lacaille F, Révillon Y, Broyer M, Daudon M: Crystalluria: A clinical useful investigation in children with primary hyperoxaluria post-transplantation. Kidney Int 1998;53:1412–1416.
16.
Daudon M, Cohen-Solal F, Barbey F, Gagnadoux MF, Knebelmann B, Jungers P: Cystine crystal volume determination: a useful tool in the management of cystinuric patients. Urol Res 2003;31:207–211.
17.
Robertson WG, Peacock M: Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone-formers. Clin Sci 1972;43:499–506.
18.
Daudon M, Cohen-Solal F, Jungers P: Does crystalluria better predict the risk of calcium oxalate stone recurrence than urinary risk indices?; in Kok DJ, Romjin HC, Verhagen PCMS, Verkoelen CF (eds): Eurolithiasis. 9th European Symposium on Urolithiasis. Maastricht, Shaker, 2001, pp 261–263.
19.
Ryall RL, Bagley CJ, Marshall VR: Independent assessment of the growth and aggregation of calcium oxalate crystals using the Coulter counter. Invest Urol 1981;18:401–405.
20.
Robertson WG, Scurr DS: Modifiers of calcium oxalate crystallization found in urine. I. Studies with a continuous crystallizer using an artificial urine. J Urol 1986;135:1322–1325.
21.
Estépa-Maurice L, Hennequin C, Marfisi C, Bader C, Lacour B, Daudon M: Fourier transform infrared microscopy identification of crystal deposits in tissues: Clinical importance in various pathologies. Am J Clin Pathol 1996;105:576–582.
22.
Daudon M, Bader CA, Jungers P: Urinary calculi: Review of classification methods and correlations with etiology. Scan Microsc 1993;7:1081–1106.
23.
Simmonds HA: 2,8-Dihydroxyadenine lithiasis. Clin Chim Acta 1986;160:103–108.
24.
Daudon M, Estépa L, Lacour B, Jungers P: Unusual morphology of calcium oxalate calculi in primary hyperoxaluria. J Nephrol 1998;11:S-1, 51–55.
25.
Maurice-Estepa L, Levillain P, Lacour B, Daudon M: Crystalline phase differentiation in urinary calcium phosphate and magnesium phosphate calculi. Scand J Urol Nephrol 1999;88:299–305.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.